Publications

AACR 2019 Posters

RTX-240, an Allogeneic Red Cell Therapeutic Expressing 4-1BBL and IL-15TP, Exhibits Potent In Vitro and In Vivo Activity and a Favorable Safety Profile

Anne-Sophie Dugast, Shannon McArdel, Maegan Hoover, Enping Hong, Shannon Curtis Leonard, Arjun Bollampalli, Douglas C. McLaughlin, Jennifer Mellen, Torben Straight Nissen, Christopher L. Carpenter, Thomas J. Wickham, Lori Melançon, and Sivan Elloul. Poster presented at the American Association for Cancer Research (AACR) annual meeting on April 2, 2019, Atlanta, GA

View Poster

RTX-224, an Allogeneic Red Cell Therapeutic Expressing IL-12 and 4-1BBL, Exhibits Potent In Vitro and In Vivo Activity and a Favorable Safety Profile

Anne-Sophie Dugast, Enping Hong, Maegan Hoover, Arjun Bollampalli, Douglas C. McLaughlin, Omkar Bhate, Timothy J. Lyford, Torben Straight Nissen, Christopher L. Carpenter, Thomas J. Wickham, Lori Melançon, and Sivan Elloul. Poster presented at the American Association for Cancer Research (AACR) annual meeting on April 2, 2019, Atlanta, GA

View Poster

Engineered Red Cell Therapeutics (RCT) as Artificial Antigen Presenting Cells Promote and Antitumor Activity of Antigen Specific T Cells

Xuqing Zhang, Shamael R. Dastagir, Naren Subbiah, Mengyao Luo, Vikram Soman, Sneha Pawar, Douglas C. McLaughlin, Nicholas Bayhi, Viral Amin, Torben Straight Nissen, Christopher L. Carpenter, Thomas J. Wickham, Lori Melançon, and Tiffany F. Chen. Poster presented at the American Association for Cancer Research (AACR) annual meeting on April 2, 2019, Atlanta, GA

View Poster